Spruce Biosciences Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Spruce BiosciencesDer Gewinn des Unternehmens wird voraussichtlich um 7.9% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 39.6% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich um 15% pro Jahr wachsen.

Wichtige Informationen

-7.9%

Wachstumsrate der Gewinne

15.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	39.6%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	14 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Insufficient Growth At Spruce Biosciences, Inc. (NASDAQ:SPRB) Hampers Share Price

May 29

Is Spruce Biosciences, Inc. (NASDAQ:SPRB) Popular Amongst Institutions?

Jan 12

Spruce Biosciences outlines milestones for 2021

Jan 06

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:SPRB - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	6	-47	N/A	N/A	2
12/31/2025	0	-43	N/A	N/A	4
12/31/2024	4	-40	N/A	N/A	1
9/30/2024	7	-39	-46	-46	N/A
6/30/2024	10	-43	-50	-50	N/A
3/31/2024	10	-47	-36	-36	N/A
12/31/2023	10	-48	-33	-33	N/A
9/30/2023	7	-49	-34	-34	N/A
6/30/2023	4	-48	-30	-30	N/A
3/31/2023	2	-47	-42	-42	N/A
12/31/2022	N/A	-46	-42	-42	N/A
9/30/2022	N/A	-44	-40	-40	N/A
6/30/2022	N/A	-44	-39	-39	N/A
3/31/2022	N/A	-44	-39	-39	N/A
12/31/2021	N/A	-42	-36	-36	N/A
9/30/2021	N/A	-41	-35	-35	N/A
6/30/2021	N/A	-40	-35	-35	N/A
3/31/2021	N/A	-34	-30	-30	N/A
12/31/2020	N/A	-30	-28	-28	N/A
9/30/2020	N/A	-24	-21	-21	N/A
6/30/2020	N/A	-17	-15	-15	N/A
3/31/2020	N/A	-15	-14	-14	N/A
12/31/2019	N/A	-13	-13	-13	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SPRB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: SPRB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: SPRB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: SPRBDie Einnahmen des Unternehmens (39.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: SPRBDie Einnahmen des Unternehmens (39.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SPRB in 3 Jahren voraussichtlich hoch sein wird

Spruce Biosciences Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates upgraded to US$1.04 loss

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target decreased by 26% to US$6.17

Consensus revenue estimates increase by 16%, EPS downgraded

Price target increased by 13% to US$8.50

Consensus revenue estimates increase by 51%

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Nasdaq Grants Spruce Biosciences an Additional 180 Calendar Days, or Until April 21, 2025, to Regain Compliance with the Minimum Closing Bid Price Requirement

Consensus EPS estimates upgraded to US$1.04 loss

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Spruce Biosciences, Inc. (NasdaqGS:SPRB) completed the acquisition of Substantially all of rights, title, interests, assets in Avexitide of Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $10 million.

New major risk - Revenue and earnings growth

Spruce Biosciences, Inc. Presents Phase 2 POWER Study Results of Tildacerfont for Treatment of Polycystic Ovary Syndrome at ENDO 2024

Insufficient Growth At Spruce Biosciences, Inc. (NASDAQ:SPRB) Hampers Share Price

Spruce Biosciences, Inc. Receives Non-Compliance Notice Regarding Nasdaq's Listing Rule 5450(a)(1)

Spruce Biosciences, Inc., Annual General Meeting, May 22, 2024

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target decreased by 26% to US$6.17

Spruce Biosciences, Inc. Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH

Spruce Biosciences, Inc. Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia

Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH

CEO & Director exercised options and sold US$64k worth of stock

Consensus revenue estimates increase by 16%, EPS downgraded

New minor risk - Share price stability

Spruce Biosciences, Inc. Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal Hyperplasia

Price target increased by 13% to US$8.50

Consensus revenue estimates increase by 51%

President & CFO exercised options and sold US$56k worth of stock

Consensus revenue estimates increase by 23%

Spruce Biosciences, Inc. Appoints Percival Barretto-Ko to Board of Directors

Consensus revenue estimates fall by 56%

Price target decreased by 18% to US$7.00

Consensus revenue estimates increase by 17%

Spruce Biosciences, Inc. announced that it expects to receive $51.08772 million in funding from a group of investors

Spruce Biosciences Provides Clinical Program Updates

Price target decreased to US$8.29

High number of new directors

Spruce Biosciences, Inc. Appoints P. J. Ramtin as Senior Vice President of Business Operations

Price target increased to US$10.40

Spruce Biosciences, Inc.(NasdaqGS:SPRB) dropped from Russell 2500 Index

High number of new directors

Spruce Biosciences, Inc. Appoints Libbie Mansell as Chief Regulatory and Quality Officer

Spruce Biosciences, Inc., Annual General Meeting, May 25, 2022

Price target decreased to US$9.83

High number of new directors

Price target decreased to US$17.60

Spruce Biosciences, Inc. Announces Details of its Phase 2 Clinical Program for Tildacerfont in Pediatric Classic CAH During its Virtual Research and Development Day

High number of new directors

Spruce Biosciences, Inc.(NasdaqGS:SPRB) dropped from Russell Microcap Growth Index

Spruce Biosciences, Inc. Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism

Independent Director has left the company

Spruce Biosciences, Inc. Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at 23rd European Congress of Endocrinology

Independent Director notifies of intention to sell stock

Spruce Biosciences, Inc. to Announces Phase 1 and 2 Data of Tildacerfont At Endocrine Society’S 2021 Annual Meeting

Jonas Hansson, Member of the Board of Directors and a Member of the Audit Committee of Spruce Biosciences, Inc. Not Intend to Stand for Reelection at the Company's 2021 Annual Meeting of Stockholders

New 90-day low: US$20.01

Is Spruce Biosciences, Inc. (NASDAQ:SPRB) Popular Amongst Institutions?

Spruce Biosciences outlines milestones for 2021

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken